Spectral decoupling for training transferable neural networks in medical imaging

Many neural networks for medical imaging generalize poorly to data unseen during training. Such behavior can be caused by overfitting easy-to-learn features while disregarding other potentially informative features. A recent implicit bias mitigation technique called spectral decoupling provably encourages neural networks to learn more features by regularizing the networks' unnormalized prediction scores with an L2 penalty. We show that spectral decoupling increases the networks' robustness for data distribution shifts and prevents overfitting on easy-to-learn features in medical images. To validate our findings, we train networks with and without spectral decoupling to detect prostate cancer on tissue slides and COVID-19 in chest radiographs. Networks trained with spectral decoupling achieve up to 9.5 percent point higher performance on external datasets. Spectral decoupling alleviates generalization issues associated with neural networks and can be used to complement or replace computationally expensive explicit bias mitigation methods, such as stain normalization in histological images.Peer reviewe

Spectral decoupling for training transferable neural networks in medical imaging

Many neural networks for medical imaging generalize poorly to data unseen during training. Such behavior can be caused by overfitting easy-to-learn features while disregarding other potentially informative features. A recent implicit bias mitigation technique called spectral decoupling provably encourages neural networks to learn more features by regularizing the networks' unnormalized prediction scores with an L2 penalty. We show that spectral decoupling increases the networks' robustness for data distribution shifts and prevents overfitting on easy-to-learn features in medical images. To validate our findings, we train networks with and without spectral decoupling to detect prostate cancer on tissue slides and COVID-19 in chest radiographs. Networks trained with spectral decoupling achieve up to 9.5 percent point higher performance on external datasets. Spectral decoupling alleviates generalization issues associated with neural networks and can be used to complement or replace computationally expensive explicit bias mitigation methods, such as stain normalization in histological images.Peer reviewe

Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: A prospective multi-institutional trial

Background: Magnetic resonance imaging (MRI) combined with targeted biopsy (TB) is increasingly used in men with clinically suspected prostate cancer (PCa), but the long acquisition times, high costs, and inter-center/reader variability of routine multiparametric prostate MRI limit its wider adoption.Methods and findings: The aim was to validate a previously developed unique MRI acquisition and reporting protocol, IMPROD biparametric MRI (bpMRI) (NCT01864135), in men with a clinical suspicion of PCa in a multi-institutional trial (NCT02241122). IMPROD bpMRI has average acquisition time of 15 minutes (no endorectal coil, no intravenous contrast use) and consists of T2-weighted imaging and 3 separate diffusion-weighed imaging acquisitions. Between February 1, 2015, and March 31, 2017, 364 men with a clinical suspicion of PCa were enrolled at 4 institutions in Finland. Men with an equivocal to high suspicion (IMPROD bpMRI Likert score 3-5) of PCa had 2 TBs of up to 2 lesions followed by a systematic biopsy (SB). Men with a low to very low suspicion (IMPROD bpMRI Likert score 1-2) had only SB. All data and protocols are freely available. The primary outcome of the trial was diagnostic accuracy-including overall accuracy, sensitivity, specificity, negative predictive value (NPV), and positive predictive value-of IMPROD bpMRI for clinically significant PCa (SPCa), which was defined as a Gleason score >= 3 + 4 (Gleason grade group 2 or higher). In total, 338 (338/364, 93%) prospectively enrolled men completed the trial. The accuracy and NPV of IMPROD bpMRI for SPCa were 70% (113/161) and 95% (71/75) (95% CI 87%-98%), respectively. Restricting the biopsy to men with equivocal to highly suspicious IMPROD bpMRI findings would have resulted in a 22% (75/338) reduction in the number of men undergoing biopsy while missing 4 (3%, 4/146) men with SPCa. The main limitation is uncertainty about the true PCa prevalence in the study cohort, since some of the men may have PCa despite having negative biopsy findings.Conclusions: IMPROD bpMRI demonstrated a high NPV for SPCa in men with a clinical suspicion of PCa in this prospective multi-institutional clinical trial.</p

Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer : A prospective multi-institutional trial

Background Magnetic resonance imaging (MRI) combined with targeted biopsy (TB) is increasingly used in men with clinically suspected prostate cancer (PCa), but the long acquisition times, high costs, and inter-center/reader variability of routine multiparametric prostate MRI limit its wider adoption. Methods and findings The aim was to validate a previously developed unique MRI acquisition and reporting protocol, IMPROD biparametric MRI (bpMRI) (NCT01864135), in men with a clinical suspicion of PCa in a multi-institutional trial (NCT02241122). IMPROD bpMRI has average acquisition time of 15 minutes (no endorectal coil, no intravenous contrast use) and consists of T2-weighted imaging and 3 separate diffusion-weighed imaging acquisitions. Between February 1, 2015, and March 31, 2017, 364 men with a clinical suspicion of PCa were enrolled at 4 institutions in Finland. Men with an equivocal to high suspicion (IMPROD bpMRI Likert score 3-5) of PCa had 2 TBs of up to 2 lesions followed by a systematic biopsy (SB). Men with a low to very low suspicion (IMPROD bpMRI Likert score 1-2) had only SB. All data and protocols are freely available. The primary outcome of the trial was diagnostic accuracy-including overall accuracy, sensitivity, specificity, negative predictive value (NPV), and positive predictive value-of IMPROD bpMRI for clinically significant PCa (SPCa), which was defined as a Gleason score >= 3 + 4 (Gleason grade group 2 or higher). In total, 338 (338/364, 93%) prospectively enrolled men completed the trial. The accuracy and NPV of IMPROD bpMRI for SPCa were 70% (113/161) and 95% (71/75) (95% CI 87%-98%), respectively. Restricting the biopsy to men with equivocal to highly suspicious IMPROD bpMRI findings would have resulted in a 22% (75/338) reduction in the number of men undergoing biopsy while missing 4 (3%, 4/146) men with SPCa. The main limitation is uncertainty about the true PCa prevalence in the study cohort, since some of the men may have PCa despite having negative biopsy findings. Conclusions IMPROD bpMRI demonstrated a high NPV for SPCa in men with a clinical suspicion of PCa in this prospective multi-institutional clinical trial.Peer reviewe

Osaajat opintiellä : täydennyskoulutuksen markkinointitutkimuksen tuloksia

Osaajat opintiellä -julkaisu perustuu markkinointitutkimukseen, joka tehtiin Turun AMK:n täydennyskoulutuksen vuoden 2002 asiakkaista. Tutkimukseen osallistui 335 henkilöä ja se suoritettiin kirjekyselynä. Vastaajilta kysyttiin taustatietoja, kuten ikää, kotipaikkaa ja koulutusta, heidän koulutusvalintojaan ja mielipiteitään täydennyskoulutuksen mainonnasta. Tutkimuksen tuloksena syntyi tietynlainen peruskuva täydennyskoulutuksen asiakkaista. Tutkimuksen avulla täydennyskoulutuksen markkinointia pyritään tehostamaan ja kohdentamaan oikeille asiakasryhmille